Q-omics provides the consensus-scored IQANK1 profile across patient tissues and cancer cell-line models. IQANK1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, IQANK1 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, IQANK1 RNA expression shows 18,818 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, COAD, and TGCT as cancer lineages where IQANK1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IQANK1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IQANK1 survival associations across molecular data types. IQANK1 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IQANK1 RNA expression–survival associations across cancer types. High IQANK1 expression shows unfavorable associations in ACC, SKCM, DLBC, MESO, PAAD and PCPG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for IQANK1 RNA expression.
This table summarizes IQANK1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for IQANK1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IQANK1 shows lower tumor expression in KIRC and higher tumor expression in COAD, HNSC, LUSC, LUAD and STAD. The COAD box plot shows higher IQANK1 RNA expression in tumor versus normal tissue (log2 FC = +3.284, t-test p < 0.001).
This table shows molecular features associated with IQANK1 in patient tissues and cancer cell lines. In patient samples, IQANK1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, IQANK1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD.
